# A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients

> **NCT01567540** · PHASE1 · TERMINATED · sponsor: **Institut National de la Santé Et de la Recherche Médicale, France** · enrollment: 3 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT01567540
- **Lead sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** New treatments available, which prevents additional recruitment.
- **Last updated:** 2014-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01567540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01567540, "A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01567540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*